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ABSTRACT
ObjeCtive
To determine whether patient controlled analgesia 
(PCA) is better than routine care in patients presenting 
to emergency departments with moderate to severe 
pain from traumatic injuries.
Design
Pragmatic, multicentre, parallel group, randomised 
controlled trial.
setting
Five English hospitals.
PartiCiPants
200 adults (71% (n=142) male), aged 18 to 75 years, 
who presented to the emergency department requiring 
intravenous opioid analgesia for the treatment of 
moderate to severe pain from traumatic injuries and 
were expected to be admitted to hospital for at least 12 
hours.
interventiOns
PCA (n=99) or nurse titrated analgesia (treatment as 
usual; n=101).
Main OutCOMe Measures
The primary outcome was total pain experienced over 
the 12 hour study period, derived by standardised area 
under the curve (scaled from 0 to 100) of each 
participant’s hourly pain scores, captured using a 
visual analogue scale. Pre-specified secondary 
outcomes included total morphine use, percentage of 
study period in moderate/severe pain, percentage of 
study period asleep, length of hospital stay, and 
satisfaction with pain management.
results
200 participants were included in the primary analyses. 
Mean total pain experienced was 47.2 (SD 21.9) for the 
treatment as usual group and 44.0 (24.0) for the PCA 
group. Adjusted analyses indicated slightly (but not 
statistically significantly) lower total pain experienced 
in the PCA group than in the routine care group (mean 
difference 2.7, 95% confidence interval −2.4 to 7.8). 
Participants allocated to PCA used more morphine in 
total than did participants in the treatment as usual 
group (mean 44.3 (23.2) v 27.2 (18.2) mg; mean 
difference 17.0, 11.3 to 22.7). PCA participants spent, on 
average, less time in moderate/severe pain (36.2% 
(31.0) v 44.1% (31.6)), but the difference was not 
statistically significant. A higher proportion of PCA 
participants reported being perfectly or very satisfied 
compared with the treatment as usual group (86% 
(78/91) v 76% (74/98)), but this was also not 
statistically significant.
COnClusiOns
PCA provided no statistically significant reduction in 
pain compared with routine care for emergency 
department patients with traumatic injuries.
trial registratiOn
European Clinical Trials Database 
EudraCT2011-000194-31; Current Controlled Trials 
ISRCTN25343280.
Introduction
Pain is defined as “an unpleasant sensory and emo-
tional experience associated with actual or potential 
tissue damage.”1  Pain is the most common reason that 
patients present to the emergency department, but it is 
often not treated effectively.2  In a national survey of 
emergency department patients, 64% reported that 
they were in pain.3  The Royal College of Emergency 
Medicine recommends that patients in severe pain 
should receive analgesia within 20 minutes of arrival in 
the emergency department, with regular reassessment 
and further action as required.4  However, effective 
analgesia is often not achieved, and almost half of 
patients surveyed thought that more could be done to 
treat their pain in the emergency department.3
Routine care for patients in moderate or severe 
pain often involves the administration of intravenous 
morphine, which is the standard opioid used in most 
hospitals and has been shown to be as effective as 
other opioids.5  In emergency departments across the 
United Kingdom, analgesia for patients in severe 
pain is provided by nurse delivered intravenous 
WhAT IS AlReAdy knoWn on ThIS TopIC
Pain is common in patients presenting to emergency departments, but it is often 
not treated effectively
Patient controlled analgesia (PCA) has been shown to be more effective than 
standard methods of analgesia delivery in other clinical areas, but very limited 
evidence relating to its use in the emergency setting exists
No previous trials have reported the use of PCA from emergency admission to the 
hospital ward
WhAT ThIS STudy AddS
No statistically significant difference was seen in effectiveness between PCA and 
treatment as usual in emergency patients who are admitted to hospital with pain 
from traumatic injuries
This is the first study to follow up participants from emergency admission to the 
hospital ward; it has therefore given a pragmatic answer to the question of whether 
PCA should be used in these patients
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 morphine over several minutes to achieve pain relief. 
This technique is safe and effective in the short term 
but places considerable demands on nursing time, 
particularly when repeated doses are needed.6
Once a patient is admitted to a hospital ward, 
severe pain may be managed using strong oral 
 opioid analgesia or advanced pain management 
techniques. Best practice includes multimodal anal-
gesia using regular paracetamol and non-steroidal 
anti-inflammatory drugs, in addition to opioids. The 
decision to admit a patient to the ward has been 
shown to delay the delivery of effective analgesia in 
the emergency department, suggesting that this 
group of patients are at particular risk of poor pain 
management.7
One solution may be to allow patients to deliver opi-
oid analgesia themselves via a patient controlled anal-
gesia (PCA) device. This device consists of a volumetric 
pump, which delivers a set intravenous dose of drug 
when a control button is pressed. The PCA system 
includes anti-siphon and anti-reflux valves to minimise 
the risk of inadvertent drug delivery. The pump has a 
safety “lockout” period when it will not deliver a further 
dose of opioid. A protocol commonly used throughout 
many UK hospitals, in settings other than the emergency 
department, uses a bolus dose of 1 mg morphine and a 
lockout period of five minutes and is derived from a 
broad evidence base.8-11 PCA has been shown to be more 
effective than standard methods of analgesia delivery in 
providing pain relief in areas such as postoperative care, 
burns, and terminal care.12-15 PCA is most effective in 
maintaining analgesia once baseline pain relief has 
been established.16
Despite the high prevalence of pain in emergency 
department patients, evidence relating to the use of 
PCA in this setting is very limited. Previous studies in 
this area provide limited evidence of the short term util-
ity of PCA in emergency patients but have not consid-
ered the management of pain over the subsequent 
hours after hospital admission.17-20 We did not identify 
any previous or current studies that combine emer-
gency department care with ongoing ward care to 
assess quality of pain relief beyond four hours, and no 
detailed analysis of the cost effectiveness of PCA in this 
setting has previously been reported.
The aim of our study was therefore to compare PCA 
morphine with routine care (nurse titrated intravenous 
morphine in the emergency department and oral or paren-
teral morphine on the wards) in adult emergency patients 
who present in moderate or severe pain due to traumatic 
injuries and are then admitted to an inpatient ward.
Methods
The detailed methodology and study protocol are 
described in a separate protocol paper.21
study design
The study comprised two contemporaneous multicentre, 
open label, randomised trials of PCA versus routine care 
in the emergency department. Patients presenting to the 
emergency department requiring intravenous analgesia 
and admission to hospital with either traumatic 
 musculoskeletal injury or non-traumatic abdominal pain 
were potentially eligible for inclusion. Key outcome mea-
sures were collected at baseline and then hourly for 12 
hours. Although two separate trials were running (one of 
patients presenting with traumatic musculoskeletal inju-
ries, the other of patients with non-traumatic abdominal 
pain), both were based on the same protocol, which is 
outlined below. Nevertheless, we have considered them 
as two separate trials, as they are powered separately. 
This paper describes the trial involving patients with 
traumatic injuries.
Participants
Eligible patients were adults presenting to the emer-
gency department with pain from traumatic injuries 
requiring intravenous opioid analgesia and hospital 
admission for at least 12 hours from the time of 
enrolment. Table 1  lists exclusion criteria.21 Study 
participants were patients who met the eligibility 
criteria and were willing and able to give informed 
consent.
recruitment
Patients underwent initial assessment and manage-
ment, including initial pain relief, according to local 
policy. A research nurse screened patients on their 
arrival at the emergency department. After initial 
assessment and pain management, a research nurse 
approached patients and gave them an information 
sheet detailing the study. If they were happy to discuss 
the study further, any questions were answered at this 
stage. Patients were then fully assessed against the 
inclusion and exclusion criteria before written informed 
consent was obtained from patients willing and able to 
participate. Patients who declined to take part were not 
obliged to give a reason, but the research nurse recorded 
any reasons given.
study procedures and data collection
After informed consent was obtained, the first study 
pain score was recorded using a visual analogue scale, 
and the participant was randomised (using a secure 
web based randomisation system) to receive either PCA 
or routine care.
Participants in both groups then received instructions 
on how to complete subsequent visual analogue scale 
scores, entering them into a mini flipchart (the partici-
pant was instructed to turn the page of the flipchart after 
an entry was made, so the previous score was not visible 
for comparison). Electronic timers (Casio F-91W digital 
watches) issued a bleep every hour as a reminder to the 
participant to complete the hourly score, but this bleep 
was not typically loud enough to wake the participant 
from sleep. The visual analogue scale was presented as 
a 10 cm horizontal line with verbal anchors at each end 
of “no pain” and “worst pain possible.” Participants 
were instructed to select the point along the line (and 
mark this point with a pen with a single vertical line) 
that reflected their current pain perception. Participants 
recorded pain scores at 60 minute intervals over a 
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12 hour period. Participants were also instructed on how 
to record periods asleep, retrospectively, on the booklet 
by using a tick box on each page.
Most other outcome data were collected for 12 hours 
from the point at which the first study pain score was 
completed. Opioid use was recorded from the pre-
scribed drugs administered as recorded on the patient’s 
drug chart during the study period (including that pre-
scribed pre-admission). We used study observation 
charts, based on standard hospital charts, for all study 
participants; these were completed as part of routine 
care by emergency department nurses and then by 
ward nurses after inpatient admission. Observations 
followed the standard of care in each centre. Typically, 
this involved observations hourly for four hours, two 
hourly for eight hours, and four hourly thereafter. In 
practice, this meant hourly vital signs in the emergency 
department and vital signs every two hours for the rest 
of the study period. Observations included heart rate, 
blood pressure, respiratory rate, oxygen saturations, 
oxygen flow rate, sedation score, and nausea score 
(0-2). A research nurse reviewed the observation charts 
after the 12 hour study period and transcribed out of 
range results into the study case report form.
Where possible, at the end of the 12 hour study period 
(or the following morning as appropriate), a research 
nurse visited participants in both groups to facilitate 
data collection. The final page of the data collection 
booklet included a five point pain management satis-
faction score ranging from “perfectly satisfied” to “not 
satisfied at all.” After the participant’s discharge, the 
research nurse obtained the length of stay in hospital 
and final diagnosis at discharge from the patient 
administration system (or equivalent) and recorded 
them in the case report form.
interventions
Participants allocated to receive routine care were 
treated with intravenous morphine while in the emer-
gency department and oral morphine (or subcutane-
ous/intramuscular morphine for those nil by mouth) 
when transferred to the hospital ward. Participants 
randomised to the PCA group received instruction from 
the research nurse in how to operate the PCA device, 
which was set up by the emergency department nurses 
and started with a 1 mg morphine bolus and a five min-
ute lockout. PCA was continued for a minimum period 
of 12 hours; in practice, the clinical team reviewed 
ongoing requirement for PCA the following morning. 
Participants in both groups were prescribed multi-
modal analgesia in addition, including paracetamol 
and a non-steroidal anti-inflammatory drug (unless 
contraindicated) and were also prescribed antiemetics 
as required.
Primary outcome measure
The primary outcome measure was the total pain 
 experienced over the 12 hour study period, as captured 
by the hourly completion of a visual analogue pain 
rating scale. We derived this by plotting data as a 
graph of visual analogue scale pain against time and 
calculating the area under the curve for each partici-
pant. This is a measure of overall pain experienced 
during the study period.22
secondary outcome measures
Secondary outcome measures included total opioid 
dose, opioid side effects, patients satisfaction with 
pain  management, proportion of study period in 
 moderate/severe pain (that is, with visual analogue 
scale >44 mm), proportion of study period spent 
 sleeping, and length of hospital stay.
randomisation, allocation concealment, 
and blinding
Randomisation (one to one) to either PCA or routine care 
was done via a secure web based randomisation system. 
Research team members accessing the randomisation 
table 1 | exclusion criteria
Criteria rationale
Patients over 75 years old Altered plasma concentrations of opioid in this age group for given 
standard dose of PCA
Patients with a reduced conscious level (Glasgow coma score <15) Will not be able to give informed consent
Inability to operate PCA device Will not be able to complete intervention
Patients who cannot understand study information (for example, owing to pre-existing 
dementia, learning difficulties, or intoxication)
Will not be able to give informed consent
Patients with chronic pain Altered pain processing or opioid tolerance
Patients who are opioid tolerant or have active opioid addiction Abnormal response to opioids or potential opioid misuse
Patients with history of renal failure Accumulation of active opioid metabolites
Allergy or other contraindication to morphine
Hypotension (systolic blood pressure <90 mm Hg) Morphine may exacerbate hypotension
Patients in police custody or in prison
Inability to gain intravenous access Will not be able to receive intravenous morphine
Patients who are likely to be definitively treated in ED and discharged or who are likely to require 
transfer for surgery direct from ED
Will not be able to complete 12 hours of visual analogue 
scale scoring
Patients who are pregnant or breast feeding Altered drug metabolism and fetal/infant opioid effects
Patients on other predetermined analgesia pathway (for example, regional anaesthesia)
Previous participation in this study
Current participation in another clinical trial of an investigational medicinal product
ED=emergency department; PCA=patient controlled analgesia.
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website did not know the allocation for an individual 
patient until the relevant details were entered and 
recruitment confirmed.
As pain experienced over subsequent hours may be 
affected by the time of day of recruitment (participants 
included later in the day would score their pain during 
night hours when they may spend a greater proportion 
of time asleep), randomisation was stratified by the 
time of the first recorded pain score (morning or after-
noon/evening), as well as by recruitment centre. 
Blinding was not possible for this study owing to the 
nature of the intervention.
sample size
The main objective of this study was to assess the 
magnitude of any difference in total pain scores 
between the PCA and routine care groups. Primary 
outcome data were collected in terms of self reported 
pain scores over time, with visual analogue scale 
measurements completed hourly over the 12 hour 
study period. We plotted data as a graph of visual 
analogue scale pain against time and used this to pro-
duce an area under the curve for each patient. This is 
a measure of overall pain experienced during the 
study period.22
Very few studies have considered the question of 
what reduction in area under the curve might be a 
clinically significant analgesic effect. One study by 
Camu et al showed that a 20% reduction in the area 
under the curve for pain on movement was associated 
with a 26% absolute increase in the proportion of 
patients reporting their global rating of pain relief as 
very good or excellent (P=0.01).23 Conservatively, 
therefore, we chose a difference in area under the 
curve of 15% between PCA and routine care groups to 
be of clinical significance. On a standardised area 
under the curve (scoring between 0 and 100), we 
expected the routine care group to have an average 
score of about 40 units, so 15% equates to a six point 
reduction. A standard deviation can be estimated 
from the research by Camu et al as about 15 units. On 
the basis of these assumptions, and using a two tailed 
two sample t test, with a type 1 error rate of 0.05, a 
sample size of 100 participants per group provides 
sufficient power (80%) to detect a between group dif-
ference of 15%.
statistical analyses
We report and present data according to the relevant 
CONSORT statement.24 The primary analyses were all 
pre-specified in a detailed statistical analysis plan 
approved by the Data Monitoring Committee before 
the analyses began. They followed an intention to 
treat approach, with the intent to treat population 
defined as all participants who completed the base-
line and at least one subsequent pain visual ana-
logue scale. Primary analyses were adjusted for the 
stratification factors (centre and time of baseline 
pain score (morning or afternoon/evening)) as fixed 
effects; unadjusted analyses are also presented. We 
present 95% confidence intervals for between group 
differences, with the significance level for hypothesis 
testing set at 5%.
We captured the primary outcome measure of total 
pain experienced by using the area under the curve 
approach and compared it between PCA and routine 
care groups by using analysis of covariance, includ-
ing the two stratification variables and the baseline 
pain score as covariates. This analysis was done 
blinded to the allocated group. We used the “trapezoi-
dal” rule to calculate the area under the curve, using 
straight lines to join visual analogue scale scores and 
calculating the area under them for the 12 hour period. 
In general, where one or more hourly scores were not 
recorded, we imputed values by linear interpolation if 
scores were recorded either side and by last observa-
tion carried forward if scores were missing at the end 
of the 12 hour period, except that we recorded such 
final scores as zero if the patient was discharged (or 
self discharged). The Trial Steering Committee and 
Data Monitoring Committee agreed these conventions 
in a detailed strategy, and reasons for missing data 
were categorised by a member of the Trial Manage-
ment Group blinded to participants’ allocated group 
wherever possible.
We similarly compared continuous secondary out-
comes between the two groups by using analysis of 
covariance, with adjustment for the two stratification 
variables. Given that some visual suggestion of poten-
tial violations of the linear model assumptions existed, 
we also produced bootstrapped confidence intervals for 
the between group differences for each outcome mea-
sure. In each instance, little difference existed between 
the normal based and bootstrapped confidence inter-
vals; for simplicity, we present only the normal based 
confidence intervals.
For the analysis of participants’ satisfaction with 
pain management, we recoded the five point scale 
(ranging from “perfectly satisfied” to “not at all sat-
isfied”) into two categories, combining “perfectly 
satisfied” and “very satisfied” into one category and 
the others into a second category. We used binary 
logistic regression to determine the odds ratio and 
95% confidence interval for the group effect, with 
adjustment for the stratification variables. Similar 
analyses compared the proportions of participants 
in terms of side effects.
sensitivity analyses
We did two pre-specified sensitivity analyses of the pri-
mary outcome measure: the first scored pain as zero for 
periods of sleep (sensitivity 1) and the second imputed 
missing pain scores due to transfers to theatre by using 
linear interpolation from the last recorded pain score to 
zero at the 12 hour time point (sensitivity 2).
Patient involvement
During the design of this study, a patient representative 
contributed to the development of the grant application 
and, later, to the study protocol and participant facing 
documentation after funding had been awarded. We 
also had a patient representative on the Trial Steering 
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Committee who helped to oversee progress of the trial 
and provided a patient’s perspective on aspects of trial 
conduct. A lay summary of the study findings will be 
made available to participants at www.medicalre-
searchplymouth.org.uk.
Results
recruitment and flow through trial
The figure outlines the flow of participants in the trial. 
Recruitment took place from July 2011 to November 
2013. Of 319 eligible patients who were approached to 
participate, 59 (18%) declined and a further 39 (12%) 
did not participate for other reasons. The remaining 
221 patients consented and were randomised: 108 to 
PCA and 113 to treatment as usual. Seven participants 
in the PCA group and 10 participants in the treatment 
as usual group were not included in the statistical 
analyses, predominately owing either to the booklets 
with the pain scores going missing or to the partici-
pant completing the pain score only once. One partic-
ipating hospital experienced some local difficulties in 
implementing the protocol as intended and only four 
patients were recruited at this site, making the 
pre-specified adjustment for centre impossible. On the 
advice of the Data Monitoring Committee, we excluded 
data from this site from the primary analyses, and the 
two participants in each group were replaced with 
newly recruited participants from other sites. Thus the 
primary analyses are based on 200 participants, 99 
randomised to PCA and 101 randomised to treatment 
as usual.
baseline characteristics
Participants were aged 18 to 75 years, and 142 (71%) 
were men (table 2). At the time of admission to the emer-
gency department, participants’ median verbal rated 
pain score was 7.0 (range 0-10). The median time from 
arrival in the emergency department to randomisation 
was 137 (range 17-385) minutes. By the time participants 
completed their first study pain score, the median 
visual analogue pain score overall was 5.3 (range 0.1-
10). The two randomised groups were similar in terms 
of most characteristics.
Primary outcome (including sensitivity analyses)
Mean total pain experienced in the PCA group was 
44.0 (SD 24.0) compared with 47.2 (21.9) in the treat-
ment as usual group (table 3). The primary analysis, 
with adjustment for centre, time of baseline pain 
score, and baseline pain score, indicated slightly (but 
not statistically significantly) lower mean total pain 
experienced in the PCA group than in the routine 
care group (mean difference 2.7, 95% confidence 
interval −2.4 to 7.8). In both pre-specified sensitivity 
analyses, the between group difference was of a similar 
magnitude.
secondary outcomes
Participants allocated to PCA used significantly more 
morphine in total than did participants in the treatment 
as usual group (mean 44.3 (SD 23.2) v 27.2 (18.2) mg; 
adjusted mean difference 17.0 (11.3 to 22.7) mg) (table 4). 
Participants in the PCA group also used significantly 
more morphine during the 12 hour study period 
(adjusted mean difference 15.8 (11.2 to 20.5) mg).
PCA participants spent, on average, less time in mod-
erate/severe pain (mean 36.2% (SD 31.0) v 44.1% (31.6)), 
but the difference was not statistically significant. We 
found no evidence of differences between the groups in 
terms of the percentage of the study period spent asleep 
or the length of hospital stay. Although a higher propor-
tion of PCA participants reported being perfectly or very 
satisfied compared with the treatment as usual group 
(78/91 (86%) v 74/98 (76%)), this did not reach  statistical 
significance (adjusted odds ratio 1.91, 95%  confidence 
interval 0.90 to 4.07).
A higher proportion of the PCA group experienced at 
least one out of range vital signs measurement com-
pared with the treatment as usual group (29/99 (29%) v 
21/101 (21%)). In particular, a significantly greater 
PCA (n=108)Treatment as usual (n=113)
Eligible patients asked to participate (n=319)
Consented patients (n=221)
Participants randomised (n=221)
Received PCA (n=108*)
Data available (n=101)
Analysed (n=99)
Received treatment as usual (n=113*)
Data from site 5 removed and
participants replaced† (n=2)
Analysed (n=101)
Data from site 5 removed and
participants replaced† (n=2)
Excluded (n=7):
  VAS booklet lost (n=2)
  Insucient VAS data (n=3)
  Retrospectively found to be ineligible
    (n=1)
  Withdrew consent (n=1)
Data available (n=103)
Excluded (n=10):
  VAS booklet lost (n=5)
  Insucient VAS data (n=2)
  Retrospectively found to be ineligible
    (n=2)
  VAS completed by nurse (n=1)
Declined to consent (n=59):
  No reason provided (n=43)
  Not interested (n=6)
  In too much pain (n=1)
  Too anxious or distressed (n=1)
  Sensitive to morphine (n=1)
  Declined further analgesia (n=1)
  Did not want to stay in hospital (n=1)
  Too tired or uncomfortable (n=1)
  Does not like PCA/prefer nurse administered (n=2)
  Patient would not talk (n=1)
  Did not want medical records shared (n=1)
Did not take part for other reasons (n=39):
  No authorised clinicians available (n=31)
  No GCP trained sta to consent (n=7)
  No further information (n=1)
Flow of participants through study. gCP=good clinical practice; PCa=patient controlled 
analgesia; vas=visual analogue scale. *8 participants transferred between treatment 
groups during 12 hour study period: 2 patients discontinued PCa and went into treatment 
as usual; 6 went the other way. †Following advice from the Data Monitoring Committee’s 
independent statistician, participants recruited at site 5 were excluded and replaced with 
newly recruited participants from other sites
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 proportion of participants in the PCA group experi-
enced one or more episodes of nausea (adjusted odds 
ratio 5.98, 1.23 to 29.04). One participant in the PCA 
group also had one instance of hypoxia.
adverse events
One serious adverse event was reported during the 
study for a participant allocated to the PCA group. 
The event was summarised as drowsiness probably 
related to opiates; the patient recovered fully. Four 
non-serious adverse effects were reported. Three 
were mild in  severity, all related to morphine and 
expected (itching). One non-serious adverse event 
was moderate in  severity and reported as drowsiness 
and vomiting; this was  considered related to mor-
phine and was expected.
table 2 | baseline and demographic data. values are percentages (numbers) unless stated otherwise
Patient controlled  
analgesia (n=99)
treatment as  
usual (n=101) all (n=200)
Demographics
Male sex 74 (73) 68 (69) 71 (142)
Mean (SD; range) age, years 43.6 (15.1; 18-74) 42.5 (14.8; 18-75) 43.1 (15.0; 18-75)
Median (IQR; range) verbal rated pain score (0-10, as 
recorded on hospital administration system)
7 (5-8; 0-10) (n=88) 7 (5-8; 0-10) (n=96) 7 (5-8; 0-10) (n=184)
Median (IQR; range) visual analogue pain score (at time 
of consent), cm
4.8 (2.9-7.3; 0.1-10) 5.4 (3.8-7.2; 0.1-9.7) 5.3 (3.1-7.3; 0.1-10)
time of recruitment
Morning (0600-1159) 16 (16) 16 (16) 16 (32)
Afternoon (1200-2200) 84 (83) 84 (85) 84 (168)
Median (IQR; range) time from arrival in emergency 
department to randomisation
144 (101-197; 24-385) 132 (93-182; 17-332) 137 (98-189.5; 17-385)
recruitment centre
Centre 1 36 (36) 35 (35) 36 (71)
Centre 2 9 (9) 9 (9) 9 (18)
Centre 3 5 (5) 5 (5) 5 (10)
Centre 4 49 (49) 51 (52) 51 (101)
Clinical diagnosis*
Burns 0 (0) 2 (2) 1 (2)
Chest wall injury 10 (10) 12 (12) 11 (22)
Lower limb fracture 28 (28) 34 (34) 31 (62)
Multiple injuries 30 (30) 22 (22) 26 (52)
Pelvis fracture 11 (11) 7 (7) 9 (18)
Spine fracture 6 (6) 10 (10) 8 (16)
Upper limb fracture 6 (6) 5 (5) 6 (11)
Soft tissue injury 6 (6) 8 (8) 7 (14)
Other 2 (2) 1 (1) 2 (3)
Preadmission analgesia
Mean (SD; range) morphine (mg): 
 Participants with pre-admission morphine 10.3 (6.7; 1.7-40.0) (n=64) 10.5 (6.0; 1.0-30.0) (n=65) 10.4 (6.3; 1.0-40.0) (n=129)
 All participants 6.7 (7.3; 0-40.0) 6.8 (7.0; 0-30.0) 6.7 (7.1; 0-40.0)
At least one dose in 24 hours before emergency 
department arrival:
 Analgesic gas 7 (7) 7 (7) 7 (14)
 Non-steroidal anti-inflammatory drug 1 (1) 2 (2) 2 (3)
 Paracetamol 15 (15) 14 (14) 15 (29)
 Weak opioid 6 (6) 2 (2) 4 (8)
 Adjuvant weak opioid 7 (7) 5 (5) 6 (12)
*Taken from participants’ discharge summaries.
table 3 | Primary outcome of total pain experienced (standardised area under curve): primary and sensitivity analyses
analysis
Mean (sD; range) adjusted analysis* unadjusted analysis
treatment as usual  
(n=101)
Patient controlled 
analgesia (n=99)
Mean difference†  
(95% Ci) P value
Mean difference†  
(95% Ci) P value
Primary 47.2 (21.9; 6.4-96.2) 44.0 (24.0; 1.0-96.8) 2.7 (−2.4 to 7.8) 0.290 3.2 (−3.2 to 9.7) 0.321
Sensitivity 1‡ 36.7 (20.9; 2.5-96.2) 32.3 (20.0; 1.0-93.3) 4.0 (−0.8 to 8.8) 0.101 4.4 (−1.3 to 10.1) 0.127
Sensitivity 2§ 46.5 (21.2; 6.4-96.2) 43.7 (24.2; 0.9-96.8) 2.3 (−2.8 to 7.4) 0.374 2.8 (−3.6 to 9.1) 0.389
*Adjusted for stratification variables (time of first pain score and recruitment centre) and baseline pain score.
†Treatment as usual minus patient controlled analgesia.
‡Pain scored as zero for periods of sleep.
§Missing pain scores for theatre withdrawals imputed using linear interpolation from last recorded pain score to zero at 12 hour time point.
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discussion
This study found no statistically significant difference 
in effectiveness between PCA and treatment as usual in 
emergency patients admitted to hospital with pain 
from traumatic injuries. Although we saw a modest 
reduction in overall pain scores and a reduction in the 
amount of time that patients spent in moderate and 
severe pain, neither of these reached statistical signifi-
cance. Moreover, the point estimate of the effect of the 
primary outcome was lower than our presumed thresh-
old for clinical importance (that is, six points). How-
ever, as our confidence interval for the difference 
between groups included this difference of six points, 
we cannot rule out the possibility that PCA provides a 
clinical benefit. Significantly more morphine was used 
in the PCA group, which may reflect under-treatment in 
the routine care group. Patients’ satisfaction also 
showed a difference in favour of PCA; the difference did 
not reach statistical significance, although it may be 
clinically important.
strengths and limitations of study
The main strength of this study was that it combined 
care in the emergency department with ongoing care 
once the patient was admitted to a hospital ward. It 
investigated the effects of PCA started in the emergency 
department but also subsequently beyond the patient’s 
emergency department stay. This is the first study to 
look at this vulnerable period between emergency care 
and inpatient management.
The lack of blinding in this study could be viewed as 
a limitation, but we did not consider blinding of 
patients or clinicians to the treatment allocation practi-
cal. The potential variability in usual treatment between 
hospitals could also be viewed as a limitation.
We emphasise that the routine care arm of this 
study may not represent real world emergency care. 
All patients who were allocated to the routine care 
group were prescribed multimodal analgesia accord-
ing to the hospital guideline, but in many cases and 
for a variety of reasons this may not always occur in 
normal practice. There may also have been a Haw-
thorne effect on the nurses who were looking after 
the patients in the routine care group; they knew that 
they were being observed, so their review of the 
patients’ analgesic requirements may have been 
influenced by this.
Comparisons with other studies and implications 
of study
Before this study started, only one small randomised 
trial of 86 adult patients with pain due to trauma pre-
senting to a UK emergency department had been pub-
lished,17  which concluded that PCA was as effective as 
standard nurse titrated analgesia. However, the trial 
collected data during the patients’ emergency depart-
ment stay only and did not continue to follow them 
after admission to a hospital ward. Three further rele-
vant studies have been reported since this study 
started, although all three were limited to a two hour 
period in the emergency department. The largest,18  a 
study done in North America, randomised 211 emer-
gency patients with abdominal pain to one of three 
groups: standard care, PCA standard dose (1 mg) 
bolus, or PCA higher dose (1.5 mg) bolus. It found a 
significant reduction in pain in both PCA groups com-
pared with standard care. A smaller study from Malay-
sia included patients presenting with pain of traumatic 
origin19 ; 96 patients in two centres were randomised 
to either standard care or PCA (1 mg boluses), with a 
significant reduction reported in pain scores in the 
PCA group compared with the standard care group. 
The same two authors reported another smaller study 
of 47 patients with traumatic injury.20 Patients were 
again randomised to receive either standard care or 
PCA (1 mg boluses). This study found similar reduc-
tions in pain scores in the PCA group compared with 
standard care.
Conclusions
This study has shown that for patients with traumatic 
injuries, PCA had no statistically significant benefit 
over standardised routine care. This is the first study to 
follow up participants from emergency admission to the 
hospital ward, and it has therefore given a pragmatic 
answer to the question of whether PCA should be used 
in these patients.
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table 4 | secondary outcomes
Outcome
Mean (sD; range) adjusted analysis* unadjusted analysis
tau (n=101) PCa (n=99)
Mean difference†  
(95% Ci) P value
Mean difference†  
(95% Ci) P value
Total morphine (mg)‡ 27.2 (18.2; 3.3-92.3) 44.3 (23.2; 5.0-128.0 −17.0 (−22.7 to −11.3) <0.001 −17.1 (−22.9 to −11.3) <0.001
Total morphine during 12 hour 
study period (mg)
12.3 (14.2; 0-82.3 28.1 (19.4; 0-103.0 −15.8 (−20.5 to −11.2) <0.001 −15.8 (−20.5 to −11.0) <0.001
Percentage of study period with 
pain VAS >44 mm
44.1 (31.6; 0-100) 36.2 (31.0; 0-100) 7.8 (−1.0 to 16.5) 0.081 7.9 (−0.8 to 16.6) 0.075
Percentage of study period asleep 22.6 (20.5; 0-76.9) 24.9 (21.2; 0-76.9) −2.3 (−8.2 to 3.5) 0.432 −2.3 (−8.2 to 3.5) 0.430
Length of hospital stay (days) 7.0 (7.8; 0.2-56.1) 9.2 (11.4; 0.3-71.9) −2.3 (−4.9 to 0.4) 0.097 −2.2 (−4.9 to 0.5) 0.112
PCA=patient controlled analgesia; TAU=treatment as usual; VAS=visual analogue scale.
*Adjusted for stratification variables (time of first pain score and recruitment centre).
†TAU minus PCA.
‡Sum of pre-admission morphine, morphine from time of admission to time of recruitment, and morphine delivered during 12 hour study period.
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